JPH0684296B2 - Multi-layer suppository - Google Patents

Multi-layer suppository

Info

Publication number
JPH0684296B2
JPH0684296B2 JP32327987A JP32327987A JPH0684296B2 JP H0684296 B2 JPH0684296 B2 JP H0684296B2 JP 32327987 A JP32327987 A JP 32327987A JP 32327987 A JP32327987 A JP 32327987A JP H0684296 B2 JPH0684296 B2 JP H0684296B2
Authority
JP
Japan
Prior art keywords
suppository
layer
base
suppositories
layers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP32327987A
Other languages
Japanese (ja)
Other versions
JPH01163118A (en
Inventor
修 広田
秀一 土屋
幹夫 古川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP32327987A priority Critical patent/JPH0684296B2/en
Publication of JPH01163118A publication Critical patent/JPH01163118A/en
Publication of JPH0684296B2 publication Critical patent/JPH0684296B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は多層坐剤に関し、更に詳細には常温で固形状の
油性基剤からなる層が複数水平に積層されてなる多層坐
剤に関する。
TECHNICAL FIELD The present invention relates to a multilayer suppository, and more particularly to a multilayer suppository in which a plurality of layers made of an oily base which is solid at room temperature are horizontally laminated.

〔従来の技術〕[Conventional technology]

従来より繁用されている坐剤は、油性基剤、水溶性基
剤、乳剤性基剤等の基剤に一種または二種以上の薬物を
配合し、均一に分散、混和した単層坐剤が一般的であ
る。
Conventionally used suppositories are single-layer suppositories in which one or more drugs are mixed in a base such as an oily base, a water-soluble base or an emulsion base and uniformly dispersed and mixed. Is common.

ところで近年、薬効成分の有効利用という観点から各種
の多層坐剤が考案されている。すなわち、多層坐剤にお
ける目的の一つは、複数の薬効成分を坐剤に配合するに
あたり、各々の薬効成分をその薬効発現に最も適した基
剤中に含有せしめることにより、各薬効成分の効果を充
分に発揮させようとするものである。このためには、あ
る薬効成分を含有する層と他の層とは分離した状態で存
在することが必要となる。そしてこのような多層坐剤
は、加温熔融した基剤を坐剤成形容器に充填した後、冷
却して固形状または半固形状にせしめ、新たなる基剤を
充填積層して、さらに冷却して凝固させることを繰り返
すことにより製造されていた(特開昭56-73017号)。
By the way, in recent years, various multilayer suppositories have been devised from the viewpoint of effective use of medicinal components. That is, one of the purposes in a multi-layered suppository is to combine a plurality of medicinal components into a suppository, and to include each medicinal component in the base most suitable for the manifestation of its medicinal properties, thereby producing the effect of each medicinal component. It is intended to make full use of. For this purpose, it is necessary that the layer containing a certain medicinal component and the other layer exist in separate states. Such a multi-layered suppository is filled with a heated and melted base in a suppository molding container, then cooled to a solid or semi-solid form, filled with a new base, laminated and further cooled. It was manufactured by repeating the process of coagulating and solidifying (JP-A-56-73017).

〔発明が解決しようとする問題点〕[Problems to be solved by the invention]

しかしながらに従来の多層坐剤には保存温度、時間によ
り積層された基剤の混和、他層への薬効成分の移行等の
問題があつた。またかかる問題は、最近坐剤に要求され
る種々の機能、すなわち、徐放化坐剤、直腸下部滞留性
坐剤等の開発の障害となつていた。
However, conventional multi-layer suppositories have problems such as mixing of the laminated bases depending on storage temperature and time, and migration of medicinal components to other layers. Further, such a problem has been an obstacle to development of various functions recently required for suppositories, that is, sustained-release suppositories, suppositories having a lower portion of the rectum, and the like.

〔問題点を解決するための手段〕[Means for solving problems]

そこで本発明者はかかる問題点を解決すべく種々検討し
てきたところ、坐剤基剤に用いる油性基剤の40℃におけ
る粘度をある特定の範囲に設定することにより、複数積
層された各層が保存中に混和することがなく、該各層に
分有される薬効成分の他層への移行も防止できることを
見い出し、本発明を完成した。
Therefore, the present inventor has made various investigations to solve such problems, and by setting the viscosity at 40 ° C. of the oily base used as a suppository base to a certain range, a plurality of laminated layers can be preserved. The present invention has been completed by discovering that it is possible to prevent the migration of the medicinal component contained in each of the layers to the other layer without being mixed therein.

すなわち、本発明は常温で固形状の油性坐剤からなる層
が複数水平に積層されてなる多層坐剤において、隣りあ
う2層の少なくとも一方が、40℃における粘度が1,000
〜100万cpである層で構成されていることを特徴とする
多層坐剤を提供するものである。
That is, the present invention is a multi-layered suppository in which a plurality of layers made of an oily suppository which are solid at room temperature are horizontally laminated, and at least one of two adjacent layers has a viscosity of 1,000 at 40 ° C.
It provides a multi-layer suppository characterized in that it is made up of layers of ~ 1 million cp.

本発明に用いられる基剤は、常温で固形状であつて油性
であれば特に制限されないが、例えばカカオ脂、ラノリ
ン脂、イソカカオ (花王製)、ウイテプゾル (ダイ
ナミツクノーベル社製)、サプシア (ガツテフオツセ
社)、SB (鐘渕化学工業製)、フアーマゾル (日本
油脂製)等の局外規ハードフアツトが挙げられる。
The base used in the present invention is solid at room temperature and oily.
It is not particularly limited as long as it is, for example, cocoa butter, lanolin
Fat, isocaca (Made by Kao), Witepsol (Die
Namitsu Nobel), Sapsia (Gatsutte Otsuse
Company), SB (Made by Kanebuchi Chemical Industry), Fuamasol (Japan
For example, an external regulation hard fat such as oil and fat) can be used.

本発明に用いられる薬効成分としては、痔疾用坐剤とし
てヒドロコルチゾン、酢酸ヒドロコルチゾン等のステロ
イド;塩酸ジブカイン、塩酸プロカイン、リドカイン等
の局所麻酔剤;グリチルレチン酸、グリチルリチン酸ジ
カリウム、アラントイン等の抗炎症剤;塩酸クロルヘキ
シジン、セトリシド等の殺菌剤;パルミチン酸レチノー
ル、dl−α−トコフエロール等のビタミン剤などがあげ
られ、解熱鎮痛・消炎用坐剤としてアスピリン、サリチ
ル酸ナトリウム、インドメタシン、オキシフエンブタゾ
ン等があげられ、抗生物質、化学療法用坐剤としてペニ
シリンGナトリウム、クロラムフエニコール、フアンギ
ゾン、スルフアジメトキシシンや各種サルフア剤などが
あげられるがここにあげたもに限定されないことはいう
までもないことである。
The medicinal ingredients used in the present invention include steroids such as hydrocortisone and hydrocortisone acetate for hemorrhoids; local anesthetics such as dibucaine hydrochloride, procaine hydrochloride and lidocaine; anti-inflammatory agents such as glycyrrhetinic acid, dipotassium glycyrrhizinate and allantoin; Examples include bactericides such as chlorhexidine hydrochloride and cetricid; vitamins such as retinol palmitate and dl-α-tocopherol. Examples of suppositories for antipyretic analgesia and anti-inflammatory include aspirin, sodium salicylate, indomethacin, oxyphenbutazone and the like. , Antibiotics, and suppositories for chemotherapy such as penicillin G sodium, chloramphenicol, fangizone, sulfadimethoxycin, and various sulfa drugs, but it goes without saying that they are not limited to these. Ah It

本発明の多層坐剤は例えば、各層を形成する常温で固形
状の油性基剤を加温熔融し、これに粘度を高める処理を
施し、該基剤を熔融温度以上の温度において坐剤成形容
器に連続的に充填した後、全体を冷却し凝固せしめるこ
とにより製造される。
The multilayer suppository of the present invention includes, for example, a suppository molding container in which a solid oily base forming each layer is heated and melted at a normal temperature and subjected to a treatment for increasing the viscosity, and the base is melted at a temperature equal to or higher than the melting temperature. It is manufactured by continuously filling and then cooling and solidifying the whole.

粘度を高める処理は、基本的には増粘剤を添加すること
によりその各層の40℃における粘度が1,000〜100万cp、
好ましくは1万〜100万cpとすることにより行なわれ
る。各層の40における粘度が1,000未満の場合には、坐
剤保存中に他層との混和が生じ、一方100万を越えると
基剤からの薬効成分の放出が遅すぎるため好ましくな
い。なお、本発明において隣りあう2層の一方の基剤は
必らずしもその粘度は上記範囲である必要はない。
To increase the viscosity, basically, by adding a thickener, the viscosity of each layer at 40 ℃ is 10 ~ 1 million cp,
It is preferably performed at 10,000 to 1,000,000 cp. When the viscosity of each layer at 40 is less than 1,000, mixing with other layers occurs during storage of suppositories, while when it exceeds 1 million, release of the medicinal component from the base is too slow, which is not preferable. In the present invention, the bases of the two adjacent layers are not necessarily required to have the viscosity within the above range.

用いる増粘剤としては、軽質無水ケイ酸、ステアリン酸
のアルミニウム塩、カルシウム塩、バリウム塩もしくは
マグネシウム塩、12−ヒドロキシステアリン酸、D−ソ
ルビトールとベンズアルデヒドの縮合物〔例えば、ゲル
オールD(新日本理化社製)〕、デキストリン脂肪酸エ
ステル〔例えば、レオパールKE(千葉製粉社製)〕、ス
チレン−エチレン−ブチレン−スチレン重合体〔例え
ば、SEBS(シエル化学社製)〕、有機性ベントナイト等
が挙げられる。
As the thickener used, light anhydrous silicic acid, aluminum salt of stearic acid, calcium salt, barium salt or magnesium salt, 12-hydroxystearic acid, a condensate of D-sorbitol and benzaldehyde [eg, Gelol D (Nippon Rika Company)), dextrin fatty acid ester [e.g. Leopard KE (Chiba Flour Milling Co.)], styrene-ethylene-butylene-styrene polymer [e.g. SEBS (Ciel Chemical Co.)], organic bentonite and the like.

これらの増粘剤は一般に前記粘度調整のためには、1〜
50重量%、特に5〜10重量%の範囲で用いるのが好まし
い。
These thickeners generally have a viscosity of 1 to
It is preferably used in an amount of 50% by weight, particularly 5 to 10% by weight.

また、本発明多層坐剤においては、少なくとも一部の層
を形成する上記油性基剤に、増粘剤に加えて膨潤剤を0.
1〜90重量%、特に10〜80重量%添加することができ
る。ここに用いられる膨潤剤としては、例えばプランタ
ゴオバタ種皮(イスパグラ種皮)、グルコマンナン、ア
ルギン酸ナトリウム、寒天、カラギーナン、グアーガ
ム、ローカストビーンガム、タマリンドガム、アラビア
ガム、カラヤガム、トラガントガム、ペクチン等の各種
食物繊維類や天然水溶性高分子類;カルボキシメチルセ
ルロース、カルボキシメチルセルロースナトリウム、カ
ルボキシメチルセルロースカルシウム、カルボキシメチ
ルセルロース、ポリアクリル酸ソーダ、ポリビニルアル
コール、ヒドロキシエチルセルロース、ヒドロキシプロ
ピルセルロース、メチルセルロース等の合成水溶性高分
子物質が挙げられる。
Further, in the multilayer suppository of the present invention, in addition to the thickener, a swelling agent is added to the oily base forming at least a part of the layer.
1 to 90% by weight, in particular 10 to 80% by weight, can be added. Examples of the swelling agent used here include various dietary fibers such as plantago ovata seed coat (ispagra seed coat), glucomannan, sodium alginate, agar, carrageenan, guar gum, locust bean gum, tamarind gum, gum arabic, karaya gum, tragacanth gum, and pectin. And natural water-soluble polymers; synthetic water-soluble polymers such as carboxymethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose, sodium polyacrylate, polyvinyl alcohol, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, etc. .

これらの中でもプランタゴオバタ種皮、アルギン酸ナト
リウム、カルボキシメチルセルロースナトリウム、カル
ボキシメチルセルロースが特に好ましい。
Among these, plantago ovata seed coat, sodium alginate, sodium carboxymethyl cellulose, and carboxymethyl cellulose are particularly preferable.

〔発明の効果〕〔The invention's effect〕

本発明の多層坐剤は保存中の各層の他層との混和、薬効
成分の他層への移行が防止された、優れた坐剤である。
従つて複数の薬効成分をその薬効発現に最も適した基剤
中に含有せしめることが可能となり、さらに最近の坐剤
に要求される種々の機能、例えば徐放化坐剤、直腸下部
滞留性坐剤等の機能を持たせることが可能となつた。
The multi-layered suppository of the present invention is an excellent suppository in which mixing with other layers during storage and migration of the medicinal components to other layers are prevented.
Therefore, it becomes possible to include a plurality of medicinal components in a base most suitable for exhibiting their medicinal properties, and various functions required for recent suppositories, such as sustained-release suppositories and subrectal suppositories. It has become possible to have functions such as agents.

〔実施例〕〔Example〕

次に、実施例を挙げて本発明を説明するが、本発明はこ
れらに限定されるものではない。
Next, the present invention will be described with reference to examples, but the present invention is not limited thereto.

実施例1 第1表に示す処方を用いて第1層と第2層とからなる多
層坐剤を調製し、得られた坐剤の第2層から第1層への
薬物の移行性、基剤の混和性について試験を行なつた。
Example 1 A multilayer suppository consisting of a first layer and a second layer was prepared using the formulation shown in Table 1, and the migration of the drug from the second layer to the first layer of the obtained suppository Tests were conducted on the miscibility of the agents.

(1)坐剤の調製法 本発明品においては、熔融した基剤に着色剤及び軽質無
水ケイ酸を添加し、十分に混合したものを坐剤成形容器
に充填し、次いで熔融した基剤に酢酸プレドニゾロンを
添加混合したものを充填積層し、全体を冷却した。
(1) Preparation method of suppository In the product of the present invention, a colorant and light anhydrous silicic acid are added to a molten base, and a sufficiently mixed mixture is filled in a suppository molding container, and then the molten base is added. The mixture to which prednisolone acetate was added and mixed was filled and laminated, and the whole was cooled.

比較品においては熔融した基剤中に着色剤を添加混合し
たものを坐剤成形容器に充填し、冷却固化した。次いで
熔融した基剤に酢酸プレドニゾロンと添加混合したもの
を充填積層し、全体を冷却固化した。
In the comparative product, a suppository molding container was filled with a colorant added to and mixed with a molten base, and cooled and solidified. Next, the melted base material was added and mixed with prednisolone acetate to be laminated, and the whole was cooled and solidified.

(2)試験方法 35°の恒温室に坐剤を保存し、10、20、30日目に以下の
試験を行つた。
(2) Test method Suppositories were stored in a thermostatic chamber at 35 ° C, and the following tests were conducted on the 10th, 20th, and 30th days.

薬物移行性 第一層基剤中の酢酸プレドニゾロン含量を高速液体クロ
マトグラフイにて測定した。その定量値(mg)を第2表
に示す。なお、n.d.は酢酸プレドニゾロンのピークが認
められなかつたことを示す。
Drug Transfer The prednisolone acetate content in the first layer base was measured by high performance liquid chromatography. The quantitative value (mg) is shown in Table 2. Note that nd indicates that the peak of prednisolone acetate was not observed.

基剤の混和性 第1層基剤中の着色剤を目安にして、第1層基剤と第2
層基剤が混和しているか否かを、次の基準により肉眼で
判定した。その結果を第2表に示す。
Miscibility of the base material The first layer base material and the second layer base material are used with the colorant in the first layer base material as a guide.
Whether or not the layer base was mixed was judged with the naked eye according to the following criteria. The results are shown in Table 2.

−:基剤の混和を認めない +:一部の基剤に混和を認める :基剤全体が均一に混和した。-: No mixture of bases is recognized +: Some bases are mixed: All bases were mixed uniformly.

実施例2 第3表に示す処方を用いて、実施例1と同様の方法にて
多層坐剤を調製し、得られた坐剤の直腸下部滞留性につ
いて検討した。
Example 2 Using the formulation shown in Table 3, a multi-layer suppository was prepared in the same manner as in Example 1, and the retention of the lower rectum of the obtained suppository was examined.

試験方法 坐剤1個をウサギ直腸内に投与し、1時間後に解剖して
直腸から結腸までを摘出、切開した。次いで2cmごとに
切断し、その各々の部分に浸透したブリリアントブルー
の色素量を測定することにより、直腸下部滞留性を評価
した。
Test Method One suppository was administered into the rectum of a rabbit, and 1 hour later, the suppository was dissected and the section from the rectum to the colon was excised and incised. Then, it was cut into 2 cm pieces, and the amount of brilliant blue dye that had penetrated into each part was measured to evaluate the retention in the lower part of the rectum.

結果 その結果、第1図に示すように本発明品A及びBは比較
品に比べ直腸下部滞留性に優れていることがわかる。
Results As shown in FIG. 1, it can be seen that the products A and B of the present invention are superior to the comparative product in retention in the lower rectum.

実施例3 第4表に示す処方を用いて実施例1と同様にして多層坐
剤を調製し、その放出特性について評価した。
Example 3 A multilayer suppository was prepared in the same manner as in Example 1 using the formulations shown in Table 4, and its release characteristics were evaluated.

放出試験は、坐剤放出試験器(富山産業(株))を用
い、放出相液として、pH7.4リン酸緩衡液500ml、液温37
±0.1℃にて行なつた。
For the release test, a suppository release tester (Toyama Sangyo Co., Ltd.) was used. As the release phase liquid, pH 7.4 phosphate buffer solution 500 ml, liquid temperature 37
Performed at ± 0.1 ° C.

その結果を第2図に示す。The results are shown in FIG.

【図面の簡単な説明】[Brief description of drawings]

第1図は実施例2において坐剤投与1時間後の、直腸下
部からの長さとブリリアントブルーの浸透量との関係を
示す図面である。第2図は、実施例3において坐剤から
の酢酸プレドニゾロンの放出性を示す図面である。
FIG. 1 is a drawing showing the relationship between the length from the lower part of the rectum and the permeation amount of brilliant blue in Example 2 one hour after the administration of suppositories. FIG. 2 is a drawing showing the release properties of prednisolone acetate from suppositories in Example 3.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】常温で固形状の油性基剤からなる層が複数
水平に積層されてなる多層坐剤において、隣りあう2層
の少なくとも一方が、40℃における粘度が1,000〜100万
cpである層で構成されていることを特徴とする多層坐
剤。
1. A multi-layered suppository in which a plurality of layers made of an oily base which are solid at room temperature are horizontally laminated, and at least one of two adjacent layers has a viscosity at 40 ° C. of 1,000 to 1,000,000.
A multilayer suppository characterized in that it is composed of layers that are cp.
【請求項2】隣りあう層の少なくとも一方の層の40℃に
おける粘度が1万〜100万cpである特許請求の範囲第1
項記載の多層坐剤。
2. The viscosity of at least one of the adjacent layers at 40 ° C. is 10,000 to 1,000,000 cp.
The multilayer suppository according to the item.
【請求項3】隣りあう層の少なくとも一方の層の40℃に
おける粘度が増粘剤の添加により調整されたものである
特許請求の範囲第1項記載の多層坐剤。
3. The multilayer suppository according to claim 1, wherein the viscosity of at least one of the adjacent layers is adjusted at 40 ° C. by adding a thickener.
JP32327987A 1987-12-21 1987-12-21 Multi-layer suppository Expired - Lifetime JPH0684296B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP32327987A JPH0684296B2 (en) 1987-12-21 1987-12-21 Multi-layer suppository

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32327987A JPH0684296B2 (en) 1987-12-21 1987-12-21 Multi-layer suppository

Publications (2)

Publication Number Publication Date
JPH01163118A JPH01163118A (en) 1989-06-27
JPH0684296B2 true JPH0684296B2 (en) 1994-10-26

Family

ID=18153013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP32327987A Expired - Lifetime JPH0684296B2 (en) 1987-12-21 1987-12-21 Multi-layer suppository

Country Status (1)

Country Link
JP (1) JPH0684296B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals

Also Published As

Publication number Publication date
JPH01163118A (en) 1989-06-27

Similar Documents

Publication Publication Date Title
CA2422356C (en) Suppository of retaining in lower region of rectum
US4814179A (en) Floating sustained release therapeutic compositions
CN1045884C (en) High dose formulations
JPS5989618A (en) Anhydrous emulsion and use
AU735815B2 (en) Composition for suppositories
JP2668730B2 (en) Sustained-release preparations using natural polymers
WO2005000310A1 (en) Multiparticulates
AU7629994A (en) Gelatin capsules containing a high concentrated acetaminophen solution
US3440320A (en) Chelated suppository and method of using same
JPS61501202A (en) Acetaminophen gelatin capsules
DE3400106A1 (en) Pharmaceutical compositions with controlled release of medicinal substance
US3325472A (en) Polycyclohexose-polyoxyethyleneglycol suppository bases
JPS63174923A (en) Vital body adhesive suppository medicine
JPH0684296B2 (en) Multi-layer suppository
US20230381100A1 (en) Gel base composition for compounding into a mucoadhesive delivery system
JPS63264534A (en) Laxative composition
JPS6024764B2 (en) Topical drugs containing indomethacin
JP4552322B2 (en) Suppository
JP2772641B2 (en) Rectal administration pharmaceutical composition
JPH0314813B2 (en)
JP2702938B2 (en) Sustained-release suppositories
JPS58140012A (en) Gradually releasing imdomethacin suppository
JP2003510269A (en) Vasopressin antagonist formulations and methods
CN105434333B (en) Mei Suoshuli suppository and its preparation method and application
MXPA00003420A (en) Suppository composition